Yield10 Bioscience Obtains Confirmation of Nonregulated Status from USDA-APHIS for its Genome-edited Camelina Line
September 05, 2017 08:35 ET
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) announced today that it has received a positive response from USDA-APHIS’s Biotechnology Regulatory Services...
CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies
August 22, 2017 07:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 22, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Taconic Biosciences Secures CRISPR License From ERS Genomics
May 30, 2017 12:20 ET
|
Taconic Biosciences
HUDSON, N.Y., May 30, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced it has signed a license agreement with...
Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas
May 13, 2017 11:05 ET
|
Editas Medicine
CAMBRIDGE, Mass., May 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating the first...
Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia
May 11, 2017 09:15 ET
|
Editas Medicine
CAMBRIDGE, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from its pre-clinical hematopoietic stem cell (HSC)...
CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT
May 08, 2017 08:00 ET
|
CRISPR Therapeutics AG
BASEL, Switzerland and CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Taconic Biosciences Launches ExpressMODEL™, a New Accelerated Model Generation Service
April 03, 2017 10:30 ET
|
Taconic Biosciences
HUDSON, N.Y., April 03, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, has launched ExpressMODEL™, an innovative and...
CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing
March 28, 2017 08:00 ET
|
CRISPR Therapeutics AG
- Patent to include CRISPR/Cas9 gene editing compositions for use in any non-cellular and cellular setting, including human and other eukaryotic cells BASEL, Switzerland, March 28, 2017 (GLOBE...
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte
March 14, 2017 07:00 ET
|
CRISPR Therapeutics AG
BASEL, Switzerland, CAMBRIDGE, Mass., and GAITHERSBURG, Md., March 14, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative...
CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference
March 02, 2017 16:30 ET
|
CRISPR Therapeutics AG
BASEL, Switzerland and CAMBRIDGE, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology...